Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CB-5339 · 1 trial · 2 indications
Incidence and nature of DLTs with CB-5339 monotherapy for MTD determination. All available safety, efficacy and PK, for RP2D determination
| Arm | Type | Description |
|---|---|---|
| CB-5339 | EXPERIMENTAL | Orally administered CB-5339 |
| Name | Type | Description |
|---|---|---|
| CB-5339 | DRUG | 25mg and 75mg capsules |
Inclusion Criteria: 1. Male or female and ≥ 18 years of age at the time of signing the consent form 2. One of the following advanced hematologic malignancies including: * Relapsed or refractory AML as defined by 2016 WHO criteria and are not candidates for curative therapies such as allogeneic ...
CB-5339 is an investigational small molecule being studied for the treatment of acute myeloid leukemia in relapse and myelodysplastic syndromes. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
CB-5339 is being developed by Eikon Therapeutics, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with certain blood cancers.
CB-5339 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies and is still being studied in clinical trials to assess its safety and potential effectiveness.
CB-5339 has been studied in a Phase 1 clinical trial with the identifier NCT04402541, titled 'Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome.' This trial has been completed and enrolled 55 participants in the United States and Australia.
CB-5339 is a distinct investigational compound developed by Eikon Therapeutics. It is not known to be the same as any other marketed drug, and no alternative names have been reported for this asset.